Original ResearchFull Report: Clinical—Alimentary TractAssociation Between Molecular Subtypes of Colorectal Cancer and Patient Survival
Section snippets
Study Population
A description of the study populations has been published elsewhere.24, 25 Briefly, SCCFR study participants included persons diagnosed with incident invasive CRC between January 1998 and June 2002 who, at the time of diagnosis, were aged 20–74 years and resided in King, Pierce, or Snohomish counties of Washington State (Supplementary Table 1). During this same period, women aged 50–74 years at CRC diagnosis and residing in 10 surrounding counties were also recruited for participation in the
Results
Among the 2080 cases with available tumor tissue, 99% (n = 2050) had information on at least one tumor marker and were included in the analysis; 65% (n = 1344) had complete data on all tumor markers. Approximately 16% of cases had tumors that were MSI-high, 13% had tumors that were BRAF-mutated, 31% had KRAS-mutated tumors, and 18% had CIMP-positive tumors. Among those with complete tumor marker data, 7% (n = 100) were classified as having the type 1 subtype, 4% (n = 55) had type 2 CRC, 26%
Discussion
In this large population-based cohort of individuals with incident invasive CRC, we found important differences in survival across CRC subtypes defined on the basis of prespecified combinations of MSI, CIMP, BRAF-mutation, and KRAS-mutation status. Patients with MSI-high subtypes of disease (ie, types 1 and 5) had the most favorable survival, and those with type 2 CRC (MSS/MSI-low, CIMP-positive, BRAF-mutated, KRAS-mutation–negative) had the highest mortality. Observed survival differences were
References (51)
- et al.
Role of the serrated pathway in colorectal cancer pathogenesis
Gastroenterology
(2010) - et al.
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Lancet Oncol
(2010) - et al.
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
Ann Oncol
(2010) - et al.
Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data
Eur J Cancer
(2010) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry
J Mol Diagn
(2008)- et al.
Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years
Eur J Cancer
(2006) - et al.
Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example
J Clin Epidemiol
(2006) - et al.
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer
Gastroenterology
(2011) - et al.
Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis
Clin Colorectal Cancer
(2011) - et al.
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Eur J Cancer
(2012)
Classification of colorectal cancer based on correlation of clinical, morphological and molecular features
Histopathology
Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women
Gastroenterology
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study
Cancer Epidemiol Biomarkers Prev
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Br J Cancer
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803
Clin Cancer Res
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF-wild-type colorectal cancers
Clin Cancer Res
KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
Br J Cancer
BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics
Cancer Epidemiol Biomarkers Prev
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
J Clin Oncol
BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis
Dis Colon Rectum
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803
Clin Cancer Res
Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer
Oncology
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
Clin Cancer Res
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
Cancer Res
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Gut
Cited by (0)
Conflicts of interest These authors disclose the following: Paul J. Limburg reported grant support received or pending from Olympus America, BENEO-Orafti Group, Bayer Healthcare, Fujinon, Inc., Boston Scientific, Astra Zeneca, and Ironwood Pharmaceuticals; he also reported having received payment for lectures from the American School of Oncology and Imedex, and royalties and stock from Exact Sciences. Daniel J. Weisenberger reported serving as a consultant to Zymo Research and receiving payment for patents and royalties from Epigenomics. Peter W. Laird also reported receiving royalties from Epigenomics, as well as receiving payment for lectures from the American Society for Clinical Oncology and for travel from the American Association for Cancer Research. The remaining authors disclose no conflicts.
Funding This work was supported by the National Cancer Institute at the National Institutes of Health (K07CA172298 to A.I.P., U01CA74794, R01CA076366, R01CA118699, R01CA107333, K05CA142885 to P.A.N.), the National Center for Advancing Translational Science at the National Institutes of Health (KL2TR000421 to A.N.B.-H.), and through cooperative agreements with members of the Colon Cancer Family Registry and Principal Investigators. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The sponsors had no role in the design and conduct of the study; no role in the collection, management, analysis, and interpretation of data; no role in preparation, review, or approval of the manuscript; and no role in the decision to submit the manuscript for publication.
Author names in bold designate shared co-first authorship.